Search

Search bills, members, committees and pages...

Sign In

JORDAN LAYSON

PreviousNext

17 federal lobbying filings, 2023 to 2026.

JORDAN LAYSON is a registered lobbyist named on 17 federal lobbying filings, 2023 to 2026.

An LDA filing reports one registrant’s income from one client for everything they worked that quarter, so a total here is the sum of whole filings and never a price for one issue or one bill.

Firms

1 they have filed under, by filings.

RegistrantFilingsReported
AMGEN, INC.17—

By year

Filings and what they reported, newest year first.

YearFilingsIncomeExpenses
20262—$5M
20255—$15.9M
20244—$11.6M
20236—$15.5M

Issues

The LDA issue codes the filings were filed under.

CodeIssueFilings
CPTCopyright/Patent/Trademark17
HCRHealth Issues17
MMMMedicare/Medicaid17
TAXTaxation/Internal Revenue Code17
TARTariff (miscellaneous tariff bills)7

Bills

The bills the filings name, by how many name them.

BillTitleFilings
H.Con.Res. 14Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth…7
H.R. 1492To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and bi…7
H.R. 1672Maintaining Investments in New Innovation Act7
S. 1040Drug Competition Enhancement Act7
S. 1041Affordable Prescriptions for Patients Act7
H.R. 1An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.6
H.R. 1968Full-Year Continuing Appropriations and Extensions Act, 20255
H.R. 2214DRUG Act5
H.R. 946ORPHAN Cures Act5
H.R. 1574RESTORE Patent Rights Act of 20254
H.R. 3152Patent Eligibility Restoration Act of 20254
H.R. 3160PREVAIL Act4
H.R. 5256340B ACCESS Act4
H.R. 5526Biosimilar Red Tape Elimination Act4
S. 1546Patent Eligibility Restoration Act of 20254
S. 1553PREVAIL Act4
H.R. 1328Supply Chain Security and Growth Act of 20253
H.R. 3269ETHIC Act3
H.R. 4317PBM Reform Act of 20253
H.R. 6166Lowering Drug Costs for American Families Act3
H.R. 6485Skinny Labels, Big Savings Act3
S. 3019No Big Blockbuster Bailouts Act3
S. 3345PBM Price Transparency and Accountability Act3
H.R. 4299Protecting Patient Access to Cancer and Complex Therapies Act2
H.R. 4581340B PATIENTS Act of 20252

Filings

The documents themselves, on the Senate’s Lobbying Disclosure site, newest first.

ClientRegistrantPeriodReportedPosted
AMGEN INCAMGEN, INC.2026 second_quarter$2.4MJul 20, 2026
AMGEN INCAMGEN, INC.2026 first_quarter$2.6MApr 20, 2026
AMGEN INCAMGEN, INC.2025 fourth_quarter$3.6MJan 20, 2026
AMGEN INCAMGEN, INC.2025 second_quarter$2.6MOct 20, 2025
AMGEN INCAMGEN, INC.2025 third_quarter$3.6MOct 20, 2025
AMGEN INCAMGEN, INC.2025 second_quarter$2.6MJul 21, 2025
AMGEN INCAMGEN, INC.2025 first_quarter$3.6MApr 21, 2025
AMGEN INCAMGEN, INC.2023 third_quarter$3MFeb 4, 2025
AMGEN INCAMGEN, INC.2024 fourth_quarter$2.8MJan 21, 2025
AMGEN INCAMGEN, INC.2024 third_quarter$2.8MOct 21, 2024
AMGEN INCAMGEN, INC.2024 second_quarter$2.7MJul 22, 2024
AMGEN INCAMGEN, INC.2024 first_quarter$3.3MApr 19, 2024
AMGEN INCAMGEN, INC.2023 fourth_quarter$3.6MJan 19, 2024
AMGEN INCAMGEN, INC.2023 third_quarter$2.2MOct 20, 2023
AMGEN INCAMGEN, INC.2023 second_quarter$2MJul 21, 2023
AMGEN INCAMGEN, INC.2023 second_quarter$2MJul 21, 2023
AMGEN INCAMGEN, INC.2023 first_quarter$2.8MApr 20, 2023